Exicure : Announces First Neurological Development Program in Friedreich's Ataxia and Expands Scientific Advisory Board

12/17/2019, CHICAGO - Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced Friedreich's ataxia (FA) as the therapeutic indication for the company's first neurology development program.
Exicure's FA program will be designed and developed with guidance from and in collaboration with FARA.


Exicure : Announces First Neurological Development Program in Friedreich's Ataxia and Expands Scientific Advisory Board